Get the Stockscreener App
2.57
2.28%
-0.06
After Hours:
2.60
0.03
+1.17%
Vivos Therapeutics Inc stock is traded at $2.57, with a volume of 160.40K.
It is down -2.28% in the last 24 hours and down -25.94% over the past month.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
See More
Previous Close:
$2.63
Open:
$2.61
24h Volume:
160.40K
Relative Volume:
0.83
Market Cap:
$15.49M
Revenue:
$14.58M
Net Income/Loss:
$-12.57M
P/E Ratio:
-0.4525
EPS:
-5.68
Net Cash Flow:
$-13.07M
1W Performance:
-19.69%
1M Performance:
-25.94%
6M Performance:
+5.76%
1Y Performance:
-24.08%
1-Day Range:
$2.38
$2.74
1-Week Range:
$2.38
$3.36
52-Week Range:
$1.91
$6.28
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Name
Vivos Therapeutics Inc
Sector
Industry
Phone
(866)908-4867
Address
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
2.57 | 15.49M | 14.58M | -12.57M | -13.07M | -5.68 |
|
ABT
Abbott Laboratories
|
131.93 | 228.81B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Vivos Therapeutics Inc Stock (VVOS) Latest News
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vivos Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Vivos Therapeutics’ Earnings Call Highlights Growth and Expansion - TipRanks
Vivos Therapeutics (VVOS) Grows Revenue by 26% and Cuts Operatin - GuruFocus
Vivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global Partners - TipRanks
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Reports Revenue Growth and Strategic Shift - TipRanks
Vivos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Vivos Therapeutics Q4 2024 revenue rises 9% By Investing.com - Investing.com UK
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update - TradingView
Vivos Earnings: Revenue Jumps 9% as FDA Approves Game-Changing Pediatric Sleep Apnea Treatment - Stock Titan
Vivos Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Decline in Short Interest - Defense World
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - The Manila Times
Medical Device Innovator Vivos Sets Key Earnings Date: What to Watch in 2024 Results - Stock Titan
Analyzing Vivos Therapeutics (NASDAQ:VVOS) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
The Silent Epidemic: How Women With Obstructive Sleep Apnea (OSA) Are Often Misdiagnosed - Yahoo Finance
Vivos Therapeutics (VVOS) Projected to Post Quarterly Earnings on Thursday - Defense World
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update - Defense World
Vivos Drives Innovation in Chronic Pain Care with Non-Invasive Treatment for Sleep Apnea - PRWeb
Anti-Snoring Devices Markets: Oral Appliances, Nasal - GlobeNewswire
Anti-Snoring Devices Markets: Oral Appliances, Nasal Devices, Position Control DevicesGlobal Forecast to 2029 with ResMed, SomnoMed, ProSomnus, and Vivos Therapeutics, and DynaFlex Dominating - Yahoo Finance UK
Comparing Vivos Therapeutics (NASDAQ:VVOS) and Regenicin (OTCMKTS:RGIN) - Armenian Reporter
Vivos Therapeutics Announces the Opening of the First Pneusomnia Integrated Medical-Dental Sleep Center - MarketScreener
Vivos Explores ‘Outright Acquisitions of Sleep Centers’ - Sleep Review
Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic alliance - Proactive Investors UK
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide - The Manila Times
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and - EIN News
Reviewing Vivos Therapeutics (NASDAQ:VVOS) & Biostage (OTCMKTS:BSTG) - Defense World
Vivos Therapeutics Inc to Host Earnings Call - ACCESS Newswire
Vivos Therapeutics to participate in Fireside Chat with Water Tower Research - Proactive Investors UK
Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm - EIN News
Revolutionary Sleep Apnea Treatment: Vivos CEO Reveals Market Strategy and Medical Partnerships - Stock Titan
Investors Give Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares A 30% Hiding - Simply Wall St
Vivos Therapeutics Enters Into At The Market Offering Agreement with H.C. Wainwright & Co., LLC**Littleton, Colo. – Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced on February 14, 2025, that the company has entered into an At The Market Offering - Defense World
Vivos Therapeutics Enters Market Offering Agreement with Wainwright - TipRanks
Vivos Therapeutics announces up to $50M mixed shelf offering - MSN
Vivos Therapeutics Inc Files For Mixed Shelf Of Up To $50 MillionSEC Filing -February 11, 2025 at 05:44 pm EST - Marketscreener.com
Cancer Breakthrough: Vivos RadioGel Eliminates 80% of Tumor Mass in Groundbreaking Trial - Stock Titan
Trapped in CPAP Dependency? Vivos Liberates OSA Patients with Non-Invasive Solution - PR Web
Vivos Therapeutics announces sale of up to 854,332 shares by selling stockholders - MSN
Vivos Therapeutics (VVOS) Stock Price, News & Analysis - MarketBeat
VVOS Stock Price and Chart — NASDAQ:VVOS — TradingView«Кавказ Пост» - «Кавказ Пост» - новости Северного Кавказа и Закавказья
Best Momentum Stocks to Buy for January 8th - MSN
Recognizing Sleep as the Sixth Vital Sign: How Vivos Is Redefining Health Care - PR Web
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 28.9% in December - Defense World
After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar - Simply Wall St
Vivos Therapeutics announces $3.5 million stock offering - Investing.com
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Vivos Therapeutics Secures $3.5M Financing Through Strategic Share Offering and Warrants - StockTitan
Vivos Therapeutics announces funding boost - Proactive Investors USA
Vivos Therapeutics Inc Stock (VVOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):